Status:

Red

Decision Date:

August 2022

Comments

RED: NICE TA808 - Fenfluramine is recommended as an add‑on to other anti-seizure medicines for treating seizures associated with Dravet syndrome in people aged 2 years and older,

RED: NICE TA1050: Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over (decision date April 2025)

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again